[Skip to Content]
[Skip to Content Landing]
Viewpoint
November 21, 2017

FDA Approval of TisagenlecleucelPromise and Complexities of a $475 000 Cancer Drug

Author Affiliations
  • 1Memorial Sloan Kettering Cancer Center, New York, New York
JAMA. 2017;318(19):1861-1862. doi:10.1001/jama.2017.15218

Approval of the drug tisagenlecleucel (Kymriah; Novartis) by the US Food and Drug Administration (FDA) for the treatment of pediatric and young adult acute lymphoblastic leukemia (ALL) in August 2017 was a landmark in oncology. The science underlying chimeric antigen receptor T cells (CAR-T) heralds a new era of treatment, and the list price of $475 000 for the new drug (delivered as a one-time infusion) definitively shattered oncology drug pricing norms.1

First Page Preview View Large
First page PDF preview
First page PDF preview
×